BridgeBio Oncology (BBOT) officer sells 78 shares at $2.37 each.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Marc Cobo, Principal Accounting Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), sold 78 shares of common stock at $2.37 per share on November 13, 2026. This transaction was executed under a Rule 10b5-1 sales plan adopted on July 24, 2026, leaving him with 13,734 shares directly after the sale. The filing was made public on November 17, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.